San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor in the weight loss drug sector in February just after revealing promising knowledge from a mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection and in March